ValiRx PLC Exercise of Warrants and Issue of Equity (4327Z)
December 15 2017 - 2:00AM
UK Regulatory
TIDMVAL
RNS Number : 4327Z
ValiRx PLC
15 December 2017
VALIRX PLC
("ValiRx" or the "Company")
EXERCISE OF WARRANTS AND ISSUE OF EQUITY
London, UK., 15 December 2017: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, has received notifications of
the exercise of warrants over 3,000,000 ordinary shares at an
exercise price of 1p and over 1,000,000 ordinary shares at an
exercise price of 5p in the Company, providing the Company with
gross proceeds of GBP80,000.
Application will be made to the London Stock Exchange to admit
the 4,000,000 new ordinary shares to trading on AIM. Admission of
the new ordinary shares is expected to occur on or around 20
December 2017. The new ordinary shares will rank pari passu with
the existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules,
following the issue of shares detailed above the enlarged issued
share capital of the Company will comprise 267,405,413 ordinary
shares of 0.1 pence each. The above figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the Company, under the Disclosure
and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20
3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20
3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP Tel: +44 (0) 20
(Nominated Adviser) 7213 0880
Liam Murray/Jo Turner/Richard
Nash
Beaufort Securities Limited Tel: +44 (0) 207
(Broker) 382 8300
Jon Belliss
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOETIBPTMBMBBAR
(END) Dow Jones Newswires
December 15, 2017 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024